WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.
Please see the Prevalence Comparison Chapter of this CSR for more information


Estimated prevalence percent ${ }^{\text {a }}$ on January 1, 2014, of the SEER $^{c}$ population diagnosed in the previous 22 years
By Age at Prevalence, Race/Ethnicity and Sex

| Age at Prevalence |  | Age Specific (Crude) |  |  |  |  |  |  |  |  |  | Age-Adjusted ${ }^{\text {f }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | All Ages | 0-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60-69 | 70-79 | 80+ | All Ages |
| Race | Sex |  |  |  |  |  |  |  |  |  |  |  |
| All Races ${ }^{\text {c }}$ | Both Sexes | $0.2466 \%$ | $0.0004 \%$ | $0.0030 \%$ | $0.0265 \%$ | $0.0994 \%$ | $0.2160 \%$ | $0.3871 \%$ | $0.6221 \%$ | $0.9034 \%$ | 1.0842\% | $0.2301 \%$ |
|  | Males | $0.2634 \%$ | $0.0002 \%$ | 0.0028\% | $0.0174 \%$ | $0.0686 \%$ | $0.1714 \%$ | $0.3751 \%$ | $0.7454 \%$ | 1.2573\% | 1.7219\% | $0.2677 \%$ |
|  | Females | $0.2304 \%$ | $0.0006 \%$ | $0.0031 \%$ | $0.0361 \%$ | $0.1304 \%$ | $0.2603 \%$ | $0.3987 \%$ | 0.5107\% | $0.6137 \%$ | 0.6999\% | $0.2059 \%$ |
| White ${ }^{\text {c }}$ | Both Sexes | $0.3240 \%$ | $0.0004 \%$ | $0.0036 \%$ | $0.0350 \%$ | $0.1328 \%$ | 0.2827\% | $0.4928 \%$ | $0.7824 \%$ | 1.1262\% | 1.3243\% | $0.2912 \%$ |
|  | Males | $0.3432 \%$ | $0.0003 \%$ | $0.0034 \%$ | 0.0229\% | 0.0891\% | 0.2187\% | $0.4694 \%$ | $0.9225 \%$ | 1.5461\% | $2.0950 \%$ | $0.3317 \%$ |
|  | Females | $0.3049 \%$ | $0.0006 \%$ | 0.0039\% | $0.0480 \%$ | $0.1789 \%$ | $0.3490 \%$ | 0.5159\% | 0.6513\% | $0.7730 \%$ | 0.8534\% | $0.2663 \%$ |
| Black ${ }^{\text {c }}$ | Both Sexes | 0.0072\% | - | - | - | $0.0031 \%$ | $0.0065 \%$ | $0.0112 \%$ | $0.0175 \%$ | $0.0421 \%$ | $0.0595 \%$ | $0.0086 \%$ |
|  | Males | $0.0069 \%$ | - | - | - | $0.0021 \%$ | $0.0049 \%$ | $0.0106 \%$ | 0.0209\% | $0.0525 \%$ | 0.0895\% | $0.0100 \%$ |
|  | Females | $0.0074 \%$ | - | - | - | $0.0040 \%$ | $0.0079 \%$ | 0.0118\% | 0.0149\% | 0.0349\% | $0.0446 \%$ | 0.0080\% |
| Asian/ <br> Pacific <br> Islander ${ }^{\text {c }}$ | Both Sexes | $0.0140 \%$ | $0.0008 \%$ | $0.0009 \%$ | $0.0026 \%$ | $0.0057 \%$ | $0.0152 \%$ | $0.0214 \%$ | $0.0321 \%$ | $0.0472 \%$ | $0.0632 \%$ | $0.0134 \%$ |
|  | Males | $0.0131 \%$ | - | - | $0.0021 \%$ | $0.0056 \%$ | 0.0114\% | $0.0182 \%$ | $0.0366 \%$ | $0.0583 \%$ | $0.0707 \%$ | $0.0136 \%$ |
|  | Females | 0.0148\% | - | - | $0.0031 \%$ | $0.0058 \%$ | $0.0186 \%$ | $0.0241 \%$ | $0.0284 \%$ | $0.0386 \%$ | 0.0585\% | $0.0134 \%$ |
| Hispanic ${ }^{\text {d }}$ | Both Sexes | $0.0326 \%$ | $0.0003 \%$ | $0.0013 \%$ | $0.0041 \%$ | 0.0182 \% | $0.0437 \%$ | $0.0789 \%$ | $0.1279 \%$ | $0.1736 \%$ | $0.2366 \%$ | $0.0467 \%$ |
|  | Males | $0.0246 \%$ | - | $0.0011 \%$ | $0.0025 \%$ | $0.0098 \%$ | $0.0263 \%$ | $0.0556 \%$ | $0.1103 \%$ | $0.1954 \%$ | 0.3119\% | $0.0426 \%$ |
|  | Females | $0.0407 \%$ | - | $0.0016 \%$ | $0.0059 \%$ | $0.0271 \%$ | $0.0618 \%$ | $0.1015 \%$ | $0.1431 \%$ | 0.1574\% | $0.1910 \%$ | 0.0522\% |

US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and $1 / 1 / 2014$
US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the census.
c d Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous $39 / 22$ years.
e (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.
e Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for $1992-2014$ SEER 13 data
f (excluding the Alaska Navtive Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.
ghi Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific compieteness index was approximated using empirical data from historical Connecticut tumor registry.
Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.
Not available.

